41 related articles for article (PubMed ID: 35659482)
21. Third-line chemotherapy and novel agents for metastatic germ cell tumors.
Veenstra CM; Vaughn DJ
Hematol Oncol Clin North Am; 2011 Jun; 25(3):577-91, ix. PubMed ID: 21570610
[TBL] [Abstract][Full Text] [Related]
22. The Role of Salvage High-Dose Chemotherapy in Relapsed Male Germ Cell Tumors.
Oing C; Lorch A
Oncol Res Treat; 2018; 41(6):365-369. PubMed ID: 29843143
[TBL] [Abstract][Full Text] [Related]
23. Management of residual disease after chemotherapy in germ cell tumors.
King J; Adra N; Einhorn LH
Curr Opin Oncol; 2020 May; 32(3):250-255. PubMed ID: 32168037
[TBL] [Abstract][Full Text] [Related]
24. [Treatment of testicular cancer].
Droz JP; Boyle H; Culine S; Fizazi K; Fléchon A; Massard C
Bull Cancer; 2013 Dec; 100(12):1319-32. PubMed ID: 24316884
[TBL] [Abstract][Full Text] [Related]
25. Beyond stage I germ cell tumors: current status regarding treatment and long-term toxicities.
Haugnes HS; Stephenson AJ; Feldman DR
Am Soc Clin Oncol Educ Book; 2014; ():e180-90. PubMed ID: 24857101
[TBL] [Abstract][Full Text] [Related]
26. Management of germ cell tumors in children: approaches to cure.
Göbel U; Calaminus G; Schneider DT; Schmidt P; Haas RJ;
Onkologie; 2002 Feb; 25(1):14-22. PubMed ID: 11893878
[TBL] [Abstract][Full Text] [Related]
27. Management of residual non-retroperitoneal disease following chemotherapy for germ cell tumor.
Sadeghi N; Badalato GM; Kates M; McKiernan JM
Urol Oncol; 2011; 29(6):837-41. PubMed ID: 21489835
[TBL] [Abstract][Full Text] [Related]
28. Management of low-stage nonseminomatous germ cell tumors of testis: SIU/ICUD Consensus Meeting on Germ Cell Tumors (GCT), Shanghai 2009.
Stephenson AJ; Aprikian AG; Gilligan TD; Oldenburg J; Powles T; Toner GC; Waters WB
Urology; 2011 Oct; 78(4 Suppl):S444-55. PubMed ID: 21986224
[TBL] [Abstract][Full Text] [Related]
29. Current medical management of patients with poor-risk metastatic germ-cell tumors.
Albany C
Curr Opin Urol; 2018 Sep; 28(5):474-478. PubMed ID: 29979236
[TBL] [Abstract][Full Text] [Related]
30. Could Aberrant Migration Explain Metachronous Germ Cell Tumors?
Kubicek P; Fenouil T; Jacquemus J; Chapuis O; Fléchon A; Dumesnil C; Faure-Conter C
Cancer Invest; 2021 Feb; 39(2):195-201. PubMed ID: 33017201
[TBL] [Abstract][Full Text] [Related]
31. Testicular germ cell tumors. Current concepts and management strategies.
Cost NG
Minerva Urol Nefrol; 2013 Jun; 65(2):133-55. PubMed ID: 23703101
[TBL] [Abstract][Full Text] [Related]
32. [Systematic review 2007: Primary treatments of testicular germ cell tumors after radical orchydectomy].
Mottet N; Rousmans S; Culine S
Bull Cancer; 2008 Feb; 95(2):205-34. PubMed ID: 18330045
[TBL] [Abstract][Full Text] [Related]
33. Promising novel therapies for relapsed and refractory testicular germ cell tumors.
Kozakova K; Mego M; Cheng L; Chovanec M
Expert Rev Anticancer Ther; 2021 Jan; 21(1):53-69. PubMed ID: 33138660
[TBL] [Abstract][Full Text] [Related]
34. [Stage-specific treatment for testicular germ cell tumours].
Heidenreich A; Bokemeyer C; Souchon R
Urologe A; 2009 Apr; 48(4):377-85. PubMed ID: 19252891
[TBL] [Abstract][Full Text] [Related]
35. High-Dose Chemotherapy and Autologous Stem Cell Transplant.
Adra N; Abonour R
Urol Clin North Am; 2019 Aug; 46(3):439-448. PubMed ID: 31277738
[TBL] [Abstract][Full Text] [Related]
36. Pharmacotherapeutic treatment of germ cell tumors: standard of care and recent developments.
Oing C; Seidel C; von Amsberg G; Oechsle K; Bokemeyer C
Expert Opin Pharmacother; 2016; 17(4):545-60. PubMed ID: 26630452
[TBL] [Abstract][Full Text] [Related]
37. Guideline discordant care in patients with metastatic germ cell tumors.
Lin JK; Jacobs LA; Blauch A; Shulman LN; Vaughn DJ
Urol Oncol; 2022 Aug; 40(8):385.e9-385.e17. PubMed ID: 35659482
[TBL] [Abstract][Full Text] [Related]
38. Management of Germ Cell Tumours of the Testes in Adult Patients: German Clinical Practice Guideline, PART II - Recommendations for the Treatment of Advanced, Recurrent, and Refractory Disease and Extragonadal and Sex Cord/Stromal Tumours and for the Management of Follow-Up, Toxicity, Quality of Life, Palliative Care, and Supportive Therapy.
Kliesch S; Schmidt S; Wilborn D; Aigner C; Albrecht W; Bedke J; Beintker M; Beyersdorff D; Bokemeyer C; Busch J; Classen J; de Wit M; Dieckmann KP; Diemer T; Dieing A; Gockel M; Göckel-Beining B; Hakenberg OW; Heidenreich A; Heinzelbecker J; Herkommer K; Hermanns T; Kaufmann S; Kornmann M; Kotzerke J; Krege S; Kristiansen G; Lorch A; Müller AC; Oechsle K; Ohloff T; Oing C; Otto U; Pfister D; Pichler R; Recken H; Rick O; Rudolph Y; Ruf C; Schirren J; Schmelz H; Schmidberger H; Schrader M; Schweyer S; Seeling S; Souchon R; Winter C; Wittekind C; Zengerling F; Zermann DH; Zillmann R; Albers P
Urol Int; 2021; 105(3-4):181-191. PubMed ID: 33486494
[TBL] [Abstract][Full Text] [Related]
39. Contemporary management of postchemotherapy testis cancer.
Daneshmand S; Albers P; Fosså SD; Heidenreich A; Kollmannsberger C; Krege S; Nichols C; Oldenburg J; Wood L
Eur Urol; 2012 Nov; 62(5):867-76. PubMed ID: 22938868
[TBL] [Abstract][Full Text] [Related]
40. [Treatment of testicular germ cell tumors relapse].
Carbonnaux M; Vinceneux A; Peyrat P; Fléchon A
Bull Cancer; 2020 Sep; 107(9):912-924. PubMed ID: 32653158
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
